Telomir Pharmaceuticals, Inc. (TELO)
TELO moved a median of -0.79% 30 minutes after news, and -1.51% by the close. How TELO actually reacts to news — the realized, point-in-time move the market made, measured across 182 labeled events over the last three years with zero look-ahead.
TELO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 169 |
| 30-min | -0.79% | 39% | 177 |
| 60-min | -0.36% | 45% | 182 |
| to close | -1.51% | 40% | 180 |
| Middle 50% of TELO reactions | -3.18% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.79% |
| Measured reactions | 182 |
Half of all Telomir Pharmaceuticals, Inc. news events land between -3.18% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TELO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TELO's baseline. Nothing else.
Recent TELO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Telomir Pharmaceuticals, For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | -4.00% | |
| Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company | Press release | GlobeNewswire | +0.80% | -4.00% | |
| Form 8-K Telomir Pharmaceuticals, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.08% | |
| Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) | Press release | GlobeNewswire | +0.00% | -5.08% | |
| Form 8-K Telomir Pharmaceuticals, For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.08% | |
| Form 8-K Telomir Pharmaceuticals, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +4.46% | |
| Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models | Press release | GlobeNewswire | -0.45% | +4.46% | |
| Form DEFA14A Telomir Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | — | +8.33% | |
| Form 10-Q Telomir Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.68% | +2.83% | |
| Form 8-K Telomir Pharmaceuticals, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models | Press release | GlobeNewswire | +0.00% | — | |
| Form DEF 14A Telomir Pharmaceuticals, For: Jul 28 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +4.31% | |
| Form 8-K Telomir Pharmaceuticals, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +4.07% | +4.88% | |
| Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model | Press release | ACCESS Newswire | +4.07% | +4.88% | |
| Form 8-K Telomir Pharmaceuticals, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.47% | |
| Form 8-K Telomir Pharmaceuticals, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +7.38% | |
| Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease | Press release | ACCESS Newswire | +0.41% | +7.38% | |
| Form 10-Q Telomir Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.39% | |
| Form 8-K Telomir Pharmaceuticals, For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | -7.35% | -4.76% | |
| Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer | Press release | ACCESS Newswire | -7.35% | -4.76% | |
| Form 8-K Telomir Pharmaceuticals, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | +0.72% | |
| Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) | Press release | ACCESS Newswire | -1.44% | +0.72% | |
| Form 8-K Telomir Pharmaceuticals, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +10.17% | |
| Form 8-K Telomir Pharmaceuticals, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +10.17% | |
| Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer | Press release | ACCESS Newswire | +1.64% | +10.17% | |
| Form 8-K Telomir Pharmaceuticals, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -8.06% | |
| Form 10-K Telomir Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.76% | -3.79% | |
| Form DEFA14A Telomir Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.89% | |
| Form DEFM14A Telomir Pharmaceuticals, | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | +0.89% | |
| Form 8-K Telomir Pharmaceuticals, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | +2.68% | |
| Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models | Press release | ACCESS Newswire | -1.79% | +2.68% | |
| Form 8-K Telomir Pharmaceuticals, For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | -1.71% | -4.27% | |
| Form PRER14A Telomir Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | -1.71% | -4.27% | |
| Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging | Press release | ACCESS Newswire | -1.71% | -4.27% | |
| Form PRER14A Telomir Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | +0.37% | -1.49% | |
| Form 8-K Telomir Pharmaceuticals, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | — | -0.04% | |
| Form 8-K Telomir Pharmaceuticals, For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +8.76% | |
| Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models | Press release | ACCESS Newswire | +0.73% | +8.76% | |
| Form 8-K Telomir Pharmaceuticals, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | +2.14% | |
| Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | Press release | ACCESS Newswire | -1.44% | -1.44% | |
| Form 8-K Telomir Pharmaceuticals, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -1.44% | |
| Form PRER14A Telomir Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | +0.00% | -1.53% | |
| Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | Press release | ACCESS Newswire | +0.00% | +3.15% | |
| Form 8-K Telomir Pharmaceuticals, For: Nov 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.15% | |
| Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | Press release | ACCESS Newswire | -3.89% | -10.49% | |
| Form 8-K Telomir Pharmaceuticals, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -3.89% | -10.49% | |
| Form 8-K Telomir Pharmaceuticals, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -3.89% | -10.49% | |
| Form PREM14A Telomir Pharmaceuticals, For: Nov 20 | SEC filing · Form PREM14A | SEC EDGAR | -3.89% | -10.49% | |
| Form 8-K Telomir Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +3.58% | -3.57% | |
| Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line | Press release | ACCESS Newswire | +3.58% | -3.57% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TELO section they belong to.
Where else TELO is measured.
TELO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Telomir Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled TELO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 182 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of TELO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TELO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.